Introduction
============

Pulmonary thromboembolism (PTE) is characterized by pulmonary circulation dysfunction and respiratory dysfunction, which is caused by a thrombus from the venous system or right heart, blocking the pulmonary artery or its branches. Due to its high morbidity and mortality, it has become the third most common cause of death among patients with cardiovascular disease ([@b1-etm-0-0-8153]).

Anti-coagulant treatment, including the use of low-molecular-weight heparin or fondaparinux, has been suggested for patients with a high or intermediate clinical probability of acute PTE, unless contraindicated, e.g. by severe renal impairment, high bleeding risk, arterial hypotension or extremes in body weight and age ([@b2-etm-0-0-8153]). However, in cases of high-risk pulmonary embolism, based on the evaluation of the risk of early pulmonary embolism-associated death, treatments to break down or remove the thrombus should be considered ([@b3-etm-0-0-8153]). For hemodynamically unstable patients with confirmed high-risk PTE, the guidelines suggest immediate thrombolysis treatment ([@b2-etm-0-0-8153]). Surgical embolectomy or catheter-based thrombus removal are becoming more common. However, even with improved safety and the development of better techniques, its application remains restricted to patients with thrombolysis treatment that is absolutely contraindicated or has failed ([@b3-etm-0-0-8153]).

For patients with acute high-risk pulmonary embolism, thrombolytic therapy may, relieve symptoms and reduce the requirement for mechanical ventilation. Hence, thrombolytic therapy improves patient outcomes by reducing right-ventricular injury, improving exercise tolerance and preventing the recurrence of pulmonary embolism, thereby improving the survival rate ([@b4-etm-0-0-8153]). The validated regimens for thrombolytic therapy include urokinase, streptokinase and recombinant tissue plasminogen activator (alteplase) ([@b5-etm-0-0-8153]). However, at present, there is no preferred thrombolytic method, since these different regimens have similar outcomes ([@b5-etm-0-0-8153]). Reteplase is a third-generation thrombolytic drug that has yet to be fully validated for treating PTE. Reteplase is also a derivative of tissue-type plasminogen activator, which has been structurally altered to retain a strong fibrin-selective thrombolytic effect ([@b6-etm-0-0-8153]). This is useful, since fibrin is one of the major components of a thrombus ([@b7-etm-0-0-8153]). Furthermore, reteplase has a reduced binding force with the hepatic scavenger receptor and a prolonged plasma half-life ([@b6-etm-0-0-8153]). In addition, reteplase may be directly administered by intravenous injection, making its use more convenient ([@b8-etm-0-0-8153]). On the basis of the significantly improved blood clot penetration and enhanced thrombolytic ability of reteplase *in vivo* ([@b6-etm-0-0-8153]), various studies on acute myocardial infarction have revealed that reteplase has a higher vascular recanalization rate when compared to alteplase and streptokinase ([@b9-etm-0-0-8153]--[@b12-etm-0-0-8153]).

However, evidence to justify its use in the treatment of pulmonary embolism is currently limited and it has yet to be validated for this type of treatment ([@b13-etm-0-0-8153]). The aim of the present study was to compare the effectiveness of reteplase with urokinase in treating high-risk pulmonary embolisms. Hence, the outcomes of patients with high-risk PTE were treated with reteplase or urokinase were retrospectively compared.

Materials and methods
=====================

### Patients and data

All patients who were rescued by the Intensive Care Unit (ICU) of Weinan Central Hospital of Shaanxi Province (Weinan, China) between June 2013 and January 2017 were retrospectively analyzed. A total of 37 patients with acute high-risk pulmonary embolism were selected for analysis in the present study. Among these patients, 17 were male and 20 were female. The age of the reteplase group was 65.50 (age, 60.25--70.50), and the age of the urokinase group was 65.50 (60.50--70.25). All patients complied with the diagnostic criteria for high-risk pulmonary embolism of either the American Heart Association ([@b14-etm-0-0-8153]) or the Chinese Society of Cardiology of the Chinese Medical Association on the diagnosis and management of acute pulmonary embolism ([@b15-etm-0-0-8153]).

All patient data were retrieved from the hospital\'s database. These data included information from the patient\'s medical charts, including age, sex, medical history, treatment outcome and complications. The criteria for inclusion in the present study were as follows: i) Adult patients diagnosed with high-risk PTE and ii) patients who underwent intravenous reteplase or urokinase thrombolytic therapy. Patients were excluded if they had any of the following: i) \>2 weeks after disease onset; ii) incomplete data set; iii) contraindications for thrombolytic treatment ([@b14-etm-0-0-8153]); iv) other forms of thrombolytic therapy, e.g. catheter-directed thrombolysis; v) severe cardiovascular disease and cerebrovascular disease. The present study conformed to the Declaration of Helsinki and was approved by the Clinical Ethics Committee of Weinan Central Hospital (Weinan, China). Patient consent was obtained at the time of hospitalization.

### Therapeutic methods

According to the treatment with different thrombolytic drugs, the subjects were divided into two groups: The reteplase group and the urokinase group. For each group of patients, the respective thrombolytic agent was applied according to the following standard procedures ([@b5-etm-0-0-8153],[@b16-etm-0-0-8153]): A dose of 18 mg of reteplase (Shandong Ahua Biological Pharmaceutical Co. Ltd.) was diluted in 20 ml saline and intravenously administered to patients in the reteplase group for 10 min, while another dose of 18 mg reteplase was administered to patients after 30 min, resulting in a total dose of 36 mg. Urokinase for injection (Tianjin Biochem Pharmaceutical Co. Ltd.) was used at a dose of 20,000 U/kg for patients in the urokinase group. This was diluted in 40 ml saline and intravenously pumped over 2 h.

After the thrombolytic therapy, the clotting ability was examined every 4 h. For each of the two groups, sequential anti-coagulant therapy with low-molecular-weight heparin calcium (dosage, 0.1 ml/10 kg) was started when the activated partial thromboplastin time dropped to twice the normal value. In addition to the thrombolytic anti-coagulant therapy, all patients were treated with oxygen therapy. Oxygen therapy or mechanical ventilation was performed according to the hypoxia state: Those patients with a partial pressure of oxygen (PO~2~) \<60 mmHg, which improved to PO~2~ ≥60 mmHg after 30 min of oxygen inhalation, were allowed to continue to inhale oxygen; patients with PO~2~ \<60 mmHg, which remained at PO~2~ \<60 mmHg after 30 min, were subjected to mechanical ventilation to achieve sufficient oxygen inhalation. The process is presented in [Fig. 1](#f1-etm-0-0-8153){ref-type="fig"}. Elevating blood pressure therapy and symptomatic treatment were provided as required.

Routine blood test, blood clotting series, assessment of liver and kidney function, D-dimer (D-D), troponin T (TNT) and pro-B-type natriuretic peptide (pro-BNP), as well as blood gas analysis were performed prior to thrombolysis. The blood gas analysis was performed with arterial blood. The other examinations were performed using venous blood for analysis. D-D was assessed by latex-enhanced immunoturbidimetry (Beijing Strong Biotechnologies Inc.), TNT and pro-BNP were assessed by electrochemiluminescence (F Hoffmann-La Roche Ltd.) and blood gas analysis was performed using an electrode.

### Outcome variables

Arterial systolic blood pressure (SBP), heart rate (HR) and change in respiratory rate (RR) were recorded prior to thrombolysis, and at 2, 4, 24 and 48 h after thrombolytic therapy. The occurrence of complications, including bleeding, was closely monitored. Furthermore, blood gas, TNT, pro-BNP and D-D were measured prior to thrombolysis and at 48 h after thrombolysis.

According to the criteria for efficacy determination in the Chinese Expert Consensus on the Diagnosis and Management of Acute Pulmonary Embolism 2010 ([@b17-etm-0-0-8153]), the improvement of dyspnea was evaluated using six levels: i) Cure: The dyspnea and other symptoms completely disappeared according to CT pulmonary angiography, pulmonary perfusion/ventilation scan or catheter-directed pulmonary angiography; ii) marked improvement: The dyspnea and other symptoms were obviously relieved or patients were successfully resuscitated (segments with defective perfusion decreased by 7--9 or the area of the lung with defective perfusion was reduced by \>75%); iii) partial improvement: The dyspnea and other symptoms were reduced (the number of segments with defective perfusion decreased by 1--6 or the area of the lung with defective perfusion was reduced by 50--75%); iv) no improvement: The dyspnea and other symptoms exhibited no significant changes; v) deterioration: The dyspnea and other symptoms were aggravated; vi) death. The outcomes were independently evaluated by three chief physicians and one deputy chief physician with more than 10 years of experience, and discrepancies were resolved by consensus. Effective thrombolysis was defined as the sum of the cure, marked improvement and partial improvement rates.

### Statistical analysis

Statistical analysis was performed using SPSS 19.0 software (IBM Corp.). The normality of distribution was evaluated using the Kolmogorov-Smirnov test. Variables with a normal distribution were compared using Student\'s t-test and their values are expressed as the mean ± standard deviation. Categorical variables were presented as the frequency (percentage). The data in [Table I](#tI-etm-0-0-8153){ref-type="table"} were analyzed between groups using the Chi-square and the t-test. The data in [Table II](#tII-etm-0-0-8153){ref-type="table"} were analyzed between groups using the Chi-square test. The data in [Table III](#tIII-etm-0-0-8153){ref-type="table"} were compared by two-way analysis of variance (ANOVA), followed by Sidak\'s multiple-comparisons test. Two-sided P-values \<0.05 were considered to indicate statistical significance. The data in [Fig. 2](#f2-etm-0-0-8153){ref-type="fig"} were analyzed using repeated-measures ANOVA with the time being the within factor and treatment (reteplase and urokinase) as the between factor. Bonferroni-adjusted post-hoc comparison was used to identify differences between paired data.

Results
=======

### Baseline characteristics

A total of 37 patients were available for analysis in the present study and the age of these patients ranged from 28 to 86 years (average age, 65.5±11.5 years). Among those patients, 16 were treated with reteplase, while 21 patients were treated with urokinase. Trauma and bed rest after surgery were the major causes of pulmonary embolism, accounting for 62.2% of cases. The other causes were hypertension (8.1%), diabetes (8.1%), cerebral infarction (5.4%), coronary heart disease (5.4%) and lower extremity varicose veins (10.8%; data not shown). However, there was no significant difference in the baseline characteristics between the two groups ([Table I](#tI-etm-0-0-8153){ref-type="table"}).

### Patient outcomes

As presented in [Table II](#tII-etm-0-0-8153){ref-type="table"}, the proportion of patients with a marked and partial improvement was comparable between the two groups. The overall effective thrombolysis rate was 93.8% (15/16) and 90.5% (19/21) for the reteplase and urokinase group, respectively, but the difference was not statistically significant (P\>0.999).

The treatment significantly improved the SBP in each of the two groups, but there was no significant difference between these two groups prior to and after thrombolytic therapy ([Fig. 2A](#f2-etm-0-0-8153){ref-type="fig"}). Furthermore, the difference in HR and RR of patients in each of these two groups was not statistically significant prior to and after thrombolytic therapy, and there was no significant difference between these two groups ([Fig. 2B and C](#f2-etm-0-0-8153){ref-type="fig"}).

There was no significant difference in PO~2~/fraction of inspired oxygen (FiO~2~), pro-BNP and D-D prior to and after treatment in the reteplase group, but TNT significantly decreased after treatment (P=0.046). There was a significant difference in PO~2~/FiO~2~ and D-D prior to vs. after thrombolysis in the urokinase group (P=0.007 and 0.001, respectively), but there was no significant difference in TNT and pro-BNP. Furthermore, there was no significant difference in PO~2~/FiO~2~, pro-BNP, TNT and D-D between the two groups after thrombolysis. TNT exhibited a downward trend after thrombolysis in the reteplase group, while TNT exhibited an upward trend after thrombolysis in the urokinase group ([Table III](#tIII-etm-0-0-8153){ref-type="table"}). The difference in the other indicators was not statistically significant.

### Complications during treatment

The hospital stay in the reteplase group was 7.00 (5.25--8.75) days, and the hospital stay in the urokinase group was 8.00 (6.25--10.00) days. In the reteplase group, three patients had subcutaneous ecchymosis at the puncture site, which was absorbed without any special treatment. Furthermore, one patient had epistaxis and errhysis at the puncture site, one patient had increased bleeding from their drainage tube on the second day after the operation and one patient had pseudoaneurysm due to a short compression time after elbow artery puncture, which was performed prior to thrombolytic therapy. These three complications improved after enhanced hemostasis by compression. Furthermore, one patient in the reteplase group had an unsuccessful resuscitation and died. In the urokinase group, all initial resuscitations were successful. One patient had epistaxis, while one patient had errhysis at the puncture site, and these two patients improved after hemostasis by compression. Furthermore, one patient died of gastric hemorrhage after 22 h of thrombolysis and one patient died of brain failure after 11 days of resuscitation. Overall, the occurrence of complications in the reteplase group was higher when compared with that in the urokinase group, but no life-threatening bleeding occurred. However, life-threatening bleeding occurred in the urokinase group.

Discussion
==========

Pulmonary embolism occurs when a detached thrombus (embolism) from any part of the venous territory becomes lodged in the pulmonary artery. Although the origin of the embolism may be venous thrombosis in any location (upper extremities, prostatic, uterine and renal veins and right heart chambers), it is a lower extremity deep vein thrombosis in most cases (90--95%), which is frequently asymptomatic. High-risk pulmonary embolism, previously referred to as massive pulmonary embolism, is characterized by hypotension or shock, accounts for \~5% of cases and is associated with early mortality in at least 15% of cases. Thrombolytic treatment is usually recommended for these patients ([@b18-etm-0-0-8153]).

In recent years, due to the in-depth understanding and improvement in diagnostic methods for PTE, the number of diagnoses have rapidly increased. For patients with high-risk pulmonary embolism, thrombolytic therapy may restore lung perfusion early, relieve symptoms, reduce the requirement for mechanical ventilation, reduce right-ventricular injury and improve exercise tolerance, which effectively prevents the recurrence of pulmonary embolism and improves the survival rate ([@b1-etm-0-0-8153],[@b2-etm-0-0-8153],[@b15-etm-0-0-8153],[@b18-etm-0-0-8153]). In the present study, reteplase and urokinase were used for the treatment of high-risk pulmonary embolism, and each of the two drugs achieved good effects by rapidly improving the patient\'s subjective symptoms and stabilizing their hemodynamics. Although the results were similar for the two groups of patients, it was suggested that the use of reteplase may reduce myocardial damage and prevent myocardial damage when compared with urokinase, with fewer major bleeding episodes. Therefore, the present study provides clinical experience for the further application of reteplase in patients with acute high-risk pulmonary embolism and suggests that it may be appropriate to broaden the application range of reteplase.

The results of the present study indicated that in terms of effectiveness, there was no significant difference between reteplase and urokinase. The two groups exhibited high levels of effectiveness and these results were supported by previous evidence suggesting that thrombolytic therapy is beneficial for high-risk PTE patients ([@b4-etm-0-0-8153],[@b5-etm-0-0-8153]) and guidelines that support the use of thrombolysis in high-risk patients ([@b18-etm-0-0-8153],[@b19-etm-0-0-8153]).

To date, certain studies have revealed significant differences in outcome among different thrombolytic agents ([@b5-etm-0-0-8153],[@b20-etm-0-0-8153]--[@b24-etm-0-0-8153]). In the present study, biomarkers and clinical parameters were compared in order to determine whether a difference exists between the reteplase and urokinase treatment groups. The results revealed only few significant differences between these two groups in certain biomarkers and clinical parameters. The improvement of TNT after thrombolysis was significant in the reteplase group, while the improvement of PO~2~/FiO~2~ and D-D was significant in the urokinase group, but the other indicators were not significantly different between the two drug treatment groups. TNT is a common marker of myocardial damage ([@b25-etm-0-0-8153]), PO~2~/FiO~2~ indicates the level of respiratory distress and D-D is a product of fibrolysis ([@b26-etm-0-0-8153]). In general, these similar results may be due to the small number of patients enrolled in the present study, preventing the differences from reaching a significant level. However, it is noteworthy that TNT continued to exhibit an upward trend after the thrombolytic therapy with urokinase, while TNT declined in the reteplase group, suggesting that reteplase may be better for improving myocardial damage.

The major concern with thrombolysis is the occurrence of complications, the most common of which is major bleeding ([@b5-etm-0-0-8153]). In the present study, complications of bleeding increased after treatment in the reteplase group, but no fatal bleeding occurred. However, one patient died of respiratory cardiopulmonary arrest due to the pulmonary embolism itself, which was not associated with reteplase. In the urokinase group, complications of fatal bleeding increased after the treatment. Furthermore, one patient treated with urokinase developed gastrointestinal hemorrhage and died, while another patient died of the pulmonary embolism itself (death from brain failure after respiratory arrest). In the present study, the complications increased following application of reteplase, which is similar to previous results ([@b14-etm-0-0-8153]), but different from the results reported by Liu *et al* ([@b27-etm-0-0-8153]). The possible reason may be that the present study is a single-center retrospective study and the sample size was small.

The present study has certain limitations. First, the small sample size resulted from the single-center nature of the study. Data from multiple centers may increase the power of evidence of the results. In order to reach exact conclusions, the sample size requires to be increased in future studies. In addition, the present study was retrospective in nature. Hence, the patients were not allocated to groups in a randomized manner. Therefore, this may have introduced a certain level of bias. Furthermore, due to lack of bedside echocardiography equipment at the ICU department in the early years, no echocardiographic data were available for all patients. In future prospective studies by our group, inclusion of these parameters will be considered. Furthermore, the patients were not followed up after discharge. Hence, it was not possible to establish the long-term outcomes for these patients.

In conclusion, reteplase, a third-generation thrombolytic drug, has not been previously validated for the treatment of pulmonary embolism. The results of the present study suggest that, although reteplase is similar to urokinase in terms of thrombolytic effectiveness for patients with high-risk pulmonary embolism, it may also reduce myocardial damage.
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![Administration protocol of the present study. PTE, pulmonary thromboembolism; APTT, activated partial thromboplastin time; LMHC, low-molecular-weight heparin calcium; PO~2~, partial oxygen pressure.](etm-18-06-4804-g00){#f1-etm-0-0-8153}

![Changes in vital variables after reteplase and urokinase thrombolytic therapy in patients with high-risk pulmonary embolism. (A) Changes in systolic blood pressure; (B) Changes in heart rate; (C) Changes in respiratory rate. Values are expressed as the mean ± standard deviation. \*P\<0.05 vs. prior to treatment for the reteplase group; ^\#^P\<0.05 vs. prior to treatment for the urokinase group.](etm-18-06-4804-g01){#f2-etm-0-0-8153}

###### 

Baseline characteristics of the patients.

  Parameter                             Reteplase (n=16)   Urokinase (n=21)   P-value
  ------------------------------------- ------------------ ------------------ ---------
  Age (years)                           66.8±5.5           64.5±12.2          0.268
  Sex (male/female)                     6/10               12/9               0.236
  BMI (kg/m^2^)                         24.5±1.9           24.3±1.9           0.391
  Previous surgery prior to the event   10 (62.5)          13 (61.9)          0.970
    Orthopedic surgery                  5 (31.2)           7 (33.3)           
    Cerebral surgery                    0                  3 (14.3)           
    Chest surgery                       2 (12.5)           2 (9.52)           
    Hepatobiliary surgery               2 (12.5)           0                  
    Breast surgery                      1 (6.25)           0                  
    Thyroid surgery                     0                  1 (4.76)           
  SBP (mmHg)                            77.0±49.7          89.3±37.2          0.264
  HR (bpm)                              80.2±60.2          75.0±42.4          0.410
  RR (bpm)                              21.7±15.3          20.1±9.9           0.389
  PO~2~/FiO~2~ (mmHg)                   178.3±62.0         167.3±97.0         0.388
  TNT (ng/l)                            0.11±0.12          0.23±0.28          0.124
  D-D (ng/l)                            13,931±24,282      28,129±32,519      0.161
  Pro-BNP (pg/ml)                       2,488±2,571        3,617±4,388        0.280
  Uric acid (µmol/l)                    299±100            352±106            0.085
  Blood glucose (mmol/l)                6.40±1.70          5.91±1.23          0.185

Values are expressed as the mean ± standard deviation or n (%). BMI, body mass index; SBP, systolic blood pressure; HR, heart rate; RR, respiratory rate; PO~2~/FiO~2~, oxygenation index; TNT, troponin T; D-D, D-dimer; Pro-BNP, pro-B-type natriuretic peptide.

###### 

Comparison of thrombolytic effects between the reteplase and urokinase groups.

  Item                             Reteplase (n=16)   Urokinase (n=21)   P-value
  -------------------------------- ------------------ ------------------ ---------
  Thrombolytic effect                                                    0.474
    Cure                           0                  0                  
    Marked improvement             11 (68.8)          13 (61.9)          
    Partial improvement            4 (25.0)           6 (28.6)           
    No improvement                 0                  0                  
    Deterioration                  0                  0                  
    Death                          1 (6.2)            2 (9.5)            
    Major bleeding complications   0                  1 (4.8)            
    Minor bleeding complications   6 (37.5)           2 (9.5)            
  Overall effective rate (%)       93.8               90.5               \>0.999

Values are expressed as n (%) unless otherwise specified. The data were compared between groups using the Chi-Square test.

###### 

Comparison of PO~2~/FiO~2~, TNT, D-D and pro-BNP prior to and after treatment (48 h) in the two groups.

  Variable              Reteplase (n=16)                                            Urokinase (n=2)                                             P-value
  --------------------- ----------------------------------------------------------- ----------------------------------------------------------- ---------
  PO~2~/FiO~2~ (mmHg)                                                                                                                           
    Baseline            178.3±62.0                                                  167.3±97.0                                                  0.914
    48 h                242.6±104.9                                                 269.8±80.7^[a](#tfn4-etm-0-0-8153){ref-type="table-fn"}^    0.583
  Pro-BNP (pg/ml)                                                                                                                               
    Baseline            2,488±2,571                                                 3,617±4,388                                                 0.473
    48 h                967±1,067                                                   2,673±2,877                                                 0.190
  TNT (µg/l)                                                                                                                                    
    Baseline            0.111±0.116                                                 0.226±0.277                                                 0.963
    48 h                0.016±0.00^9[a](#tfn4-etm-0-0-8153){ref-type="table-fn"}^   0.991±2.610                                                 0.078
  D-D (µg/l)                                                                                                                                    
    Baseline            13,931±24,282                                               28,129±32,519                                               0.080
    48 h                2,342±1,224                                                 5,313±3,547^[a](#tfn4-etm-0-0-8153){ref-type="table-fn"}^   0.889

Values are expressed as the mean ± standard deviation. The data were compared by two-way analysis of variance, followed by Sidak\'s multiple-comparisons test.

P\<0.05, vs. baseline. PO~2~/FiO~2~, oxygenation index; TNT, troponin T; D-D, D-dimer; Pro-BNP, pro-B-type natriuretic peptide.
